A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II study of gemcitabine- Vinorelbine combination in a 3-weekly schedule as
first line chemotherapy in patients with metastatic breast cancer. Eighty patients with
measurable disease will be enrolled in the study. Gemcitabine will be used at 1000 mg/m2,
vinorelbine at 25mg/m2. Every cycle, vinorelbine will be administered before gemcitabine.
After the initial dose, modifications of Gemcitabine and vinorelbine doses are allowed based
on patient toxicity
Study therapy may continue until:
- There is evidence of progressive disease
- The patient experiences unacceptable toxicity.
- The investigator decides that the patient should be discontinued
- The patient requests discontinuation
- The patient has received 6 cycles of the regimen(if the physician decides to continue
after 6 cycles-this will be done after consultation with the sponsor)
- Discontinuation from study therapy is indicated according to the protocol It's the
investigator's responsibility to strictly stick to the protocol procedures. It needs to
be discussed with Lilly medical designee in advance when any special situation occurs
which has not been defined in protocol.
After patients discontinue from study therapy, they proceed to the post-study follow up phase
of the study. Assessments to take place during this phase are outlined in the protocol.